Autopsy report · NCT01554176

Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Low Enrollment”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 months before it started.
Ran for about 1 year 4 months before it stopped.
129 participants enrolled.
Results were posted on the registry 3 years 2 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Merck Sharp & Dohme LLC
Sponsor type: Industry
Conditions: Major Depressive Disorder, Recurrent
Interventions: Filorexant; Placebo
Participants: 129

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.